Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE:002907)
China
· Delayed Price · Currency is CNY 14.06
+0.13 (0.93%)
Apr 30, 2026, 12:54 PM CST
SHE:002907 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 815.21 | 764.14 | 680.84 | 774.72 | 837.23 | Upgrade
|
| Other Revenue | 11.93 | 10.68 | 10.7 | 10.47 | 8.91 | Upgrade
|
| Revenue | 827.14 | 774.82 | 691.54 | 785.18 | 846.14 | Upgrade
|
| Revenue Growth (YoY) | 6.75% | 12.04% | -11.93% | -7.20% | -4.12% | Upgrade
|
| Cost of Revenue | 353.96 | 332.91 | 312.45 | 320.55 | 400.53 | Upgrade
|
| Gross Profit | 473.18 | 441.91 | 379.1 | 464.63 | 445.61 | Upgrade
|
| Selling, General & Admin | 317.2 | 308.36 | 263.88 | 292.53 | 297.82 | Upgrade
|
| Research & Development | 89.76 | 59.13 | 78.12 | 58.82 | 41.72 | Upgrade
|
| Other Operating Expenses | 13.22 | 12.11 | 11.01 | 12.34 | 11.58 | Upgrade
|
| Operating Expenses | 420.38 | 381.01 | 351.31 | 367.04 | 350.65 | Upgrade
|
| Operating Income | 52.8 | 60.9 | 27.78 | 97.59 | 94.95 | Upgrade
|
| Interest Expense | -0.14 | - | -0.95 | -14.42 | -18.22 | Upgrade
|
| Interest & Investment Income | 14.79 | 10.32 | 9.81 | 11.5 | 16.4 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.02 | 0 | -0 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.3 | 0.27 | -0.17 | -0.03 | -0.03 | Upgrade
|
| EBT Excluding Unusual Items | 67.17 | 71.49 | 36.48 | 94.64 | 93.11 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.42 | 1.38 | -4.67 | -2.61 | -1.33 | Upgrade
|
| Gain (Loss) on Sale of Assets | 10.25 | - | 0.06 | - | -0.01 | Upgrade
|
| Asset Writedown | -0.44 | -0.03 | -2.37 | -0.17 | - | Upgrade
|
| Other Unusual Items | -0.94 | 20.6 | 13.3 | 16.37 | 11.65 | Upgrade
|
| Pretax Income | 77.46 | 93.44 | 42.8 | 108.24 | 103.42 | Upgrade
|
| Income Tax Expense | 22.25 | 16.71 | 10.1 | 9.84 | 11.64 | Upgrade
|
| Earnings From Continuing Operations | 55.21 | 76.73 | 32.7 | 98.4 | 91.78 | Upgrade
|
| Minority Interest in Earnings | 9.88 | - | - | - | - | Upgrade
|
| Net Income | 65.09 | 76.73 | 32.7 | 98.4 | 91.78 | Upgrade
|
| Net Income to Common | 65.09 | 76.73 | 32.7 | 98.4 | 91.78 | Upgrade
|
| Net Income Growth | -15.17% | 134.66% | -66.77% | 7.21% | -22.99% | Upgrade
|
| Shares Outstanding (Basic) | 417 | 418 | 418 | 403 | 401 | Upgrade
|
| Shares Outstanding (Diluted) | 417 | 418 | 418 | 403 | 401 | Upgrade
|
| Shares Change (YoY) | -0.05% | 0.02% | 3.60% | 0.49% | 0.06% | Upgrade
|
| EPS (Basic) | 0.16 | 0.18 | 0.08 | 0.24 | 0.23 | Upgrade
|
| EPS (Diluted) | 0.16 | 0.18 | 0.08 | 0.24 | 0.23 | Upgrade
|
| EPS Growth | -15.13% | 134.61% | -67.92% | 6.69% | -23.04% | Upgrade
|
| Free Cash Flow | 47.68 | 145.62 | 126.52 | -47.57 | 26.21 | Upgrade
|
| Free Cash Flow Per Share | 0.11 | 0.35 | 0.30 | -0.12 | 0.07 | Upgrade
|
| Dividend Per Share | 0.075 | 0.085 | 0.050 | 0.070 | 0.050 | Upgrade
|
| Dividend Growth | -11.77% | 70.00% | -28.57% | 40.00% | 78.57% | Upgrade
|
| Gross Margin | 57.21% | 57.03% | 54.82% | 59.17% | 52.66% | Upgrade
|
| Operating Margin | 6.38% | 7.86% | 4.02% | 12.43% | 11.22% | Upgrade
|
| Profit Margin | 7.87% | 9.90% | 4.73% | 12.53% | 10.85% | Upgrade
|
| Free Cash Flow Margin | 5.76% | 18.79% | 18.30% | -6.06% | 3.10% | Upgrade
|
| EBITDA | 138.5 | 147.74 | 109.68 | 172.13 | 164.7 | Upgrade
|
| EBITDA Margin | 16.74% | 19.07% | 15.86% | 21.92% | 19.46% | Upgrade
|
| D&A For EBITDA | 85.7 | 86.84 | 81.9 | 74.54 | 69.74 | Upgrade
|
| EBIT | 52.8 | 60.9 | 27.78 | 97.59 | 94.95 | Upgrade
|
| EBIT Margin | 6.38% | 7.86% | 4.02% | 12.43% | 11.22% | Upgrade
|
| Effective Tax Rate | 28.72% | 17.89% | 23.59% | 9.09% | 11.25% | Upgrade
|
| Revenue as Reported | 827.14 | 774.82 | 691.54 | 785.18 | 846.14 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.